While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.status: publishe
Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinom...
Coinfections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally...
After the use of antiviral drugs in the treatment of hepatitis B virus (HBV) infection, we found new...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Three hundred and fifty million people worldwide are estimated to be chronically infected with hepat...
Three agents have been approved for the treatment of chronic hepatitis B virus (HBV): interferon-alp...
International audienceLicensed oral agents for antiviral therapy in patients with chronic hepatitis ...
Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment ...
The management of chronic hepatitis B poses specific problems in the presence of human immunodeficie...
Primarily resulting as a spin-off of the search for effective anti-HSV or anti-HIV agents, several c...
Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a majo...
Chronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic he...
A significant proportion of human immunodeficiency virus (HIV) infected patients are coinfected with...
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting mai...
Effective antiviral therapy for chronic hepatitis B virus (HBV) infection is important since ∼400 mi...
Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinom...
Coinfections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally...
After the use of antiviral drugs in the treatment of hepatitis B virus (HBV) infection, we found new...
Chronic hepatitis B virus (HBV) infection remains an important global burden with an estimated 240 m...
Three hundred and fifty million people worldwide are estimated to be chronically infected with hepat...
Three agents have been approved for the treatment of chronic hepatitis B virus (HBV): interferon-alp...
International audienceLicensed oral agents for antiviral therapy in patients with chronic hepatitis ...
Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment ...
The management of chronic hepatitis B poses specific problems in the presence of human immunodeficie...
Primarily resulting as a spin-off of the search for effective anti-HSV or anti-HIV agents, several c...
Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a majo...
Chronic hepatitis B virus (HBV) infection affects over 350 million individuals worldwide. Chronic he...
A significant proportion of human immunodeficiency virus (HIV) infected patients are coinfected with...
The primary goal of therapy in patients with chronic hepatitis B is suppression and long-lasting mai...
Effective antiviral therapy for chronic hepatitis B virus (HBV) infection is important since ∼400 mi...
Hepatitis B virus (HBV) is an important cause of end-stage liver disease and hepatocellular carcinom...
Coinfections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally...
After the use of antiviral drugs in the treatment of hepatitis B virus (HBV) infection, we found new...